FIELD: medicine, virology, vaccines. SUBSTANCE: invention relates to preparing live antiinfluenza intranasal vaccine for children that corresponds to an actual virus A/Nanchang/933/95 (H3N2). Vaccine strain A/47/Nanchang/95/13 (H3N2) is a reassortant obtained by breeding epidemic virus A/Nanchang/933/95 (H3N2) with cold-adopted and temperature-sensitive virus A/Leningrad/ /134/47/57 (H2N2) - an attenuation donor. Strain is harmless for children and its properties ensure a possibility to obtain reassortant vaccine strains from the again appearing epidemic viruses. Strain A/47/Nanchang/95/13 (H3N2) is actively multiplicated in developing chicken embryos at optimal temperature 34 C. Strain shows temperature-sensitivity and cold-adaptation. From an epidemic virus reassortant inherited two genes encoding surface proteins (hemagglutinin and neuraminidase) and six genes encoding nonglycosylated proteins from attenuation donor. Strain A/47/Nangchang/95/13 (H3N2) is an areactogenic for children at intranasal administration. Vaccine strain A/47/Nanchang/95/13 (H3N2) by its biological properties and reactive indices corresponds to requirements for vaccine strain according Pharmacopoeia points 42-298 VS-89 with respect to vaccine for intranasal using for children 3-14 ages. EFFECT: strain indicated above, enhanced effectiveness of vaccine proposed. 1 tbl, 1 ex
